Janssen Pharmaceutica Nv

Celgene Corporation

Polytherics Limited

Fu-An Kang

Zhihua Sui

David F McComsey

John Fitzgerald Traverse

Christopher A Teleha

Francisco Velazquez

Chaozhong Cai

Ronald K Russell

Sanjeevani Ghone

Michael Peter Winters

Nareshkumar F Jain

Shawn T Branum

Nagy E Fawzy

Nareshkumar Jain

Sean Wesley Smith

Sylvia J Degrado

Senzhi Zhao

Ian Glassford

Michael Reuman

Michael P Winters

Provided herein are thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV). Also provided herein are uses of these thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV), pharmaceutical compositions and formulations in the treatment of various diseases, including but not limited to diseases or disorders associated with an activated immune system (e.g., multiple sclerosis and psoriasis).

Thiazolidinone and oxazolidinone compounds and formulations

Provided herein are novel maytansinoid compounds of general formula I. Also provided herein are conjugates comprising the compounds linked to a binding protein via a linker, and conjugating reagents comprising the compounds attached via a linker to at least one functional group capable of reacting with a binding protein. Also provided herein are pharmaceutical compositions comprising the compounds and conjugates, therapeutic methods and uses involving the compounds and conjugates, for example in cancer therapy, and novel synthetic processes.

Cytotoxic agents and conjugates thereof

The present invention comprises compounds of Formula (I). wherein: R, R, R, R, R, Zand Zare as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Octahydro-cyclopentapyrrolyl antagonists of CCR2

The present invention comprises compounds of Formula (I). wherein: R, R, R, R, R, R, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Fused cyclopentyl antagonists of CCR2

The present invention is directed to 7 oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.

Oxa-steroids derivatives as selective progesterone receptor modulators

Growing community of inventors

Collegeville, PA, United States of America

Fu-An Kang